Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.

doi:10.1158/1078-0432.CCR-24-0863

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2024

Marrero Richard J, Wu Huiyun, Cao Xueyuan, Parcha Phani Krishna, Elsayed Abdelrahman H, Inaba Hiroto, Kuo Dennis John, Degar Barbara A, Heym Kenneth, Taub Jeffrey W, Lacayo Norman, Pui Ching-Hon, Ribeiro Raul C, Rubnitz Jeffrey E, Pounds Stanley B, Lamba Jatinder K

Abstract excerpt

PURPOSE: Cytarabine (also known as ara-C) has been the backbone of acute myeloid leukemia (AML) chemotherapy for more than five decades. Recent pharmacogenomics-based 10-SNP ara-C (ACS10) scores showed low ACS10 (≤0) to be associated with poor outcomes in patients with AML treated with standard chemotherapy. Here, we evaluated the ACS10 score in the context of three different induction I regimens in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Cytarabine

Share to Infant

Share to Leukemia, Myeloid, Acute

Share to Pharmacogenetics

Share to Precision Medicine

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 39078289
DOI: 10.1158/1078-0432.CCR-24-0863
PMCID: PMC11444877

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.PMID 39078289Read ↗

Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.Semantic proximity Read ↗

Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.Semantic proximity Read ↗

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia.Semantic proximity Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

An Ensemble Model for Acute Myeloid Leukemia Risk Stratification Recommendations by Combining Machine Learning with Clinical GuidelinesSemantic proximity Read ↗

Pharmacogenomics and the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.Semantic proximity Read ↗

Development and Validation of a Novel RNA Sequencing–Based Prognostic Score for Acute Myeloid LeukemiaSemantic proximity Read ↗

Risk stratification for younger and older patients with acute myeloid leukemia through transcriptomics, clinical data and machine learningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.